Schafer Cullen Capital Management Inc. lowered its position in shares of GlaxoSmithKline PLC (NYSE:GSK) by 13.4% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,996,833 shares of the pharmaceutical company’s stock after selling 308,551 shares during the period. Schafer Cullen Capital Management Inc. owned about 0.08% of GlaxoSmithKline PLC worth $86,103,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently modified their holdings of the stock. Colony Group LLC grew its position in GlaxoSmithKline PLC by 5.7% during the 2nd quarter. Colony Group LLC now owns 72,299 shares of the pharmaceutical company’s stock worth $3,118,000 after acquiring an additional 3,917 shares during the last quarter. High Falls Advisors Inc grew its position in GlaxoSmithKline PLC by 4.9% during the 2nd quarter. High Falls Advisors Inc now owns 8,212 shares of the pharmaceutical company’s stock worth $354,000 after acquiring an additional 384 shares during the last quarter. 1st Global Advisors Inc. grew its position in GlaxoSmithKline PLC by 0.4% during the 2nd quarter. 1st Global Advisors Inc. now owns 5,271 shares of the pharmaceutical company’s stock worth $227,000 after acquiring an additional 19 shares during the last quarter. Verition Fund Management LLC bought a new stake in GlaxoSmithKline PLC during the 2nd quarter worth $1,300,000. Finally, BB&T Investment Services Inc. bought a new stake in GlaxoSmithKline PLC during the 2nd quarter worth $556,000. Institutional investors and hedge funds own 9.28% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This report was first reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://www.truebluetribune.com/2017/10/13/schafer-cullen-capital-management-inc-trims-position-in-glaxosmithkline-plc-gsk.html.
A number of brokerages recently weighed in on GSK. Citigroup Inc. restated a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Thursday, July 27th. TheStreet lowered GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a research report on Wednesday, July 26th. Argus restated a “buy” rating and set a $50.00 price objective on shares of GlaxoSmithKline PLC in a research report on Thursday, August 31st. Zacks Investment Research upgraded GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $47.00 price objective on the stock in a research report on Tuesday, July 18th. Finally, J P Morgan Chase & Co restated a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Thursday, September 14th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $44.67.
GlaxoSmithKline PLC (NYSE:GSK) last posted its earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.68 by $0.02. The company had revenue of $9.36 billion for the quarter, compared to analysts’ expectations of $9.52 billion. GlaxoSmithKline PLC had a return on equity of 114.93% and a net margin of 6.48%.
The firm also recently announced a quarterly dividend, which was paid on Thursday, October 12th. Investors of record on Friday, August 11th were paid a $0.491 dividend. The ex-dividend date of this dividend was Wednesday, August 9th. This is a boost from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. This represents a $1.96 annualized dividend and a dividend yield of 4.79%. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is presently 198.00%.
GlaxoSmithKline PLC Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.